Internet-delivered Cognitive Behavioral Therapy Following Myocardial Infarction (MI-CBT)

Myocardial infarction (MI) is one of the leading cause s of health loss globally, representing a large proportion of general disability. Anxiety and depression occur in 20-30 percent of patients following MI and have been identified as risk factors for recurrent adverse cardiac event. The purpose of our this study is to develop and evaluate a disease specific cognitive behavioral therapy (C BT) protocol to reduce cardia anxiety, depression, increase physical inactivity and quality of life (Q oL) in patients following MI

Study Overview

• Status: Completed
• Conditions: Myocardial Infarction; CBT; Exposure; Cardiac Anxiety
• Intervention / Treatment: Behavioral: MI-CBT

Detailed Description

The study will include 30 patients. The MI-specific CBT lasts for 8 weeks and is therapist guided and delivered via internet via a secure digital platform by licensed psychologists expertise in CBT for cardiac disease or final year psychologist under supervision. During treatment, the psychologists will have direct access to a cardiologist assigned to the project and treatments are conducted in close interdisciplinary collaboration to ensure patient safety

• Study Type: Interventional
• Enrollment (Actual): 23
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Sweden
  • Stockholm, Sweden
    • Karolinska Institutet

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

( - )MI ≥ 6 months before assessment ( - )Age 18-75 years endorsed cardiac anxiety that leads to significant distress or interferes with daily life (Cardiac Anxiety Questionnaire (CAQ); score ≥20) ( - ) On optimal medical treatment ( - )Able to read and write in Swedish.

Exclusion Criteria:

( - ) heart failure with severe systolic dysfunction (ejection fraction ≤ 35%) ( - ) significant valvular disease ( - ) planned coronary artery bypass surgery or other invasive therapy ( - ) other severe medical illness ( - )any medical restriction to physical exercise ( - )severe psychiatric disorder, severe depression, or risk of suicide ( - )alcohol dependency

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: MI-CBT via the Internet; The MI-specific CBT will consist of 8 modules delivered via the Internet with home assignments that can be reviewed and reported in the research groups secure platform.	Behavioral: MI-CBT; Education of MI and common reactions, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
12-Item Short-Form Health Survey (SF-12)	General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life. General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life. General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.	Baseline
12-Item Short-Form Health Survey (SF-12)	General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life. General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life. General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.	2 months from baseline
12-Item Short-Form Health Survey (SF-12)	General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life. General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life. General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.	8 months from baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cardiac anxiety questionnaire	Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.	Baseline
Cardiac anxiety questionnaire	Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.	2 months from baseline
Cardiac anxiety questionnaire	Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.	8 months from baseline
Body Sensation Questionnaire	Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations. Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations. Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.	Baseline
Body Sensation Questionnaire	Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations. Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations. Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.	2 months from baseline
Body Sensation Questionnaire	Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations. Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations. Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.	8 months from baseline
Patient Health Questionnaire-9	Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression	Baseline
Patient Health Questionnaire-9	Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression	2 months from baseline
Patient Health Questionnaire-9	Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression	8 months from baseline
Generalized Anxiety Disorder 7-item	General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.	Baseline
Generalized Anxiety Disorder 7-item	General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.	2 months from baseline
Generalized Anxiety Disorder 7-item	General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.	8 months from baseline
The Godin Leisure-time Exercise	Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.	Baseline
The Godin Leisure-time Exercise	Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.	2 months from baseline
The Godin Leisure-time Exercise	Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.	8 months from baseline
Tampas Scale for Kinesophobia-Heart version	Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.	Baseline
Tampas Scale for Kinesophobia-Heart version	Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.	2 months from baseline
Tampas Scale for Kinesophobia-Heart version	Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.	8 months from baseline
Client satisfaction Questionnaire	Treatment satisfaction, score ranging from 0 to 32, with a higher score indication more satisfaction with the treatment.	Baseline
Client satisfaction Questionnaire	Treatment satisfaction, score ranging from 0 to 32, with a higher score indication more satisfaction with the treatment.	2 months from baseline
Adverse events	Potential adverse reactions to the treatment. Participants will be asked to report and rate the short- and long term discomfort of the adverse event on a scale from 0 ('did not affect me at all') and 3 ('affected me very negatively').	2 months from treatment
Adverse events	Potential adverse reactions to the treatment. Participants will be asked to report and rate the short- and long term discomfort of the adverse event on a scale from 0 ('did not affect me at all') and 3 ('affected me very negatively').	8 months from treatment
Symptom Checklist (SCL)	Measures frequency and severity of 16 cardiac-related symptoms. Scoring range from 0 to 64 for frequency with a greater score indicating more frequent symptoms, and from range from 0 to 48 for severity, with a greater score indicating more severe symptoms	Baseline
Symptom Checklist (SCL)	Measures frequency and severity of 16 cardiac-related symptoms. Scoring range from 0 to 64 for frequency with a greater score indicating more frequent symptoms, and from range from 0 to 48 for severity, with a greater score indicating more severe symptoms	2 months from baseline
Symptom Checklist (SCL)	Measures frequency and severity of 16 cardiac-related symptoms. Scoring range from 0 to 64 for frequency with a greater score indicating more frequent symptoms, and from range from 0 to 48 for severity, with a greater score indicating more severe symptoms	8 months from baseline
Perceived stress scale (4-item version)	Stress reactivity. A greater score indicate more perceived stress.	Baseline
Perceived stress scale (4-item version)	Stress reactivity. A greater score indicate more perceived stress.	2 months from Baseline
Perceived stress scale (4-item version)	Stress reactivity. A greater score indicate more perceived stress.	8 months from Baseline
Insomnia Severity Index	Measurement of sleep	Baseline
Insomnia Severity Index	Measure of insomnia, score ranging from 0-20, with a higher score indicating more severe insomnia	2 months from Baseline
Insomnia Severity Index	Measure of insomnia, score ranging from 0-20, with a higher score indicating more severe insomnia	8 months from Baseline
The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)	Measure of post traumatic stress, score ranging from 0-80, with a higher score indicating more post traumatic stress.	Baseline
The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)	Measure of post traumatic stress, score ranging from 0-80, with a higher score indicating more post traumatic stress.	2 months from Baseline
The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)	Measure of post traumatic stress, score ranging from 0-80, with a higher score indicating more post traumatic stress.	8 months from Baseline

Collaborators and Investigators

• Sponsor: Karolinska Institutet

Study record dates

Study Major Dates

• Study Start (Actual): October 28, 2021
• Primary Completion (Actual): December 10, 2022
• Study Completion (Actual): December 10, 2022

Study Registration Dates

• First Submitted: November 10, 2021
• First Submitted That Met QC Criteria: November 10, 2021
• First Posted (Actual): November 22, 2021

Study Record Updates

• Last Update Posted (Estimate): January 10, 2023
• Last Update Submitted That Met QC Criteria: January 9, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Ischemia; Pathologic Processes; Necrosis; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Myocardial Infarction; Infarction
• Other Study ID Numbers: CBT-MI

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No